| 标题 |
345 Treatment with amlitelimab—a novel non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody—reduces IL-22 serum levels in a phase 2a randomized, placebo-controlled trial in patients with moderate-to-severe atopic dermatitis |
| 网址 | |
| DOI | |
| 其它 |
期刊:British Journal of Dermatology 作者:Stephan Weidinger; Michael Cork; Adam Reich; Thomas Bieber; Sally Gilbert; et al 出版日期:2023 |
| 求助人 | |
| 下载 | 该求助完结已超 24 小时,文件已从服务器自动删除,无法下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)